{
  "id": 2256142,
  "title": "Gut-immune signaling drives blood-brain barrier damage in pediatric allogeneic stem cell transplant",
  "url": "https://urgent.news/2026/08/20/gut-immune-signaling-drives-blood-brain-barrier-damage-in-pediatric",
  "topic": "science",
  "section": "Science",
  "published": "2026-08-20T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.08.17.745172v1?rss=1"
  },
  "original_language": "en",
  "account": "Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a life-saving treatment for children battling high-risk blood disorders. However, this therapy can also increase the risk of long-term brain and cognitive problems, particularly in young patients. Scientists are still trying to understand the reasons behind these neurological issues. While gastrointestinal problems and immune system reactions after allo-HSCT have been well-studied, their role in harming the central nervous system is still unclear. By analyzing clinical biomarkers, researchers have discovered evidence of blood-brain barrier (BBB) dysfunction in pediatric allo-HSCT patients. This damage is linked to a protein called IL-6 and a decrease in brain-derived neurotrophic factor. Before the transplant, problems in the children's intestinal lining also resulted in leakage in the BBB after the procedure, suggesting a disrupted connection between the gut and the brain. In laboratory tests, damage to the gut caused immune system activation, which led to the death of brain microvascular endothelial cells (BMECs) and changes in their structure. When plasma taken from allo-HSCT recipients was exposed to these cells, it also caused cell death. Surprisingly, both types of damage to BMECs could be stopped by blocking IL-6 signaling or adding a substance called propionate, which is produced by the gut microbiota. Overall, these findings show that immune system signals can make the BBB leaky, both in the clinic and in the lab, and that they are a key cause of BBB damage in children who have undergone allo-HSCT.",
  "summary": "Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a life-saving therapy for children with high-risk hematological diseases. However, allo-HSCT also confers the risk of long-term neurocognitive dysfunction, particularly in pediatric recipients, and the mechanisms underlying this remain poorly understood. While gastrointestinal toxicities and immune responses following allo-HSCT…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}